CCNB1 and non-small cell lung carcinoma: Western blot analysis indicated that treatment with acetyl-bufalin dose-dependently inhibited the expressions of cyclin B1 and CDC2 in human NSCLC cells (Fig. 3b and Supplementary Fig. S2d).